NASDAQ: $SERA
Strategic Financial Leadership for Sera Prognostics
Sera Prognostics, Inc., a leader in precision medicine for maternal and neonatal health, has officially announced the appointment of Scott Gleason as its new Chief Financial Officer (CFO). This strategic hire marks a significant milestone for the company as it continues to advance its mission of improving pregnancy outcomes through advanced proteomics-based diagnostics.
About Scott Gleason
Scott Gleason brings a wealth of financial expertise and corporate leadership to the Sera Prognostics team. His appointment is expected to play a critical role in the company’s ongoing growth and operational strategy. As CFO, Gleason will be responsible for overseeing the company’s financial operations, including capital allocation, financial reporting, and long-term strategic planning.
The Mission Ahead
Sera Prognostics focuses on providing clinicians with high-value, actionable information to help improve the health of pregnant individuals and their babies. With a refined executive team in place, the company remains dedicated to its primary objectives:
- Continuing the commercialization of its diagnostic products.
- Advancing its pipeline of proteomic biomarker research.
- Strengthening its financial position to support long-term innovation.
- Enhancing value for shareholders through disciplined fiscal management.
This leadership transition underscores the company’s commitment to maintaining a robust financial foundation while continuing to address significant unmet medical needs in maternal health.
Source: Read More